foxo4-dri senolytic or senomorphic (Proxofim) 10mg*10 vials - Nexus peptides Targeted Apoptosis of Senescent Cells
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging PMC The FOXO4 peptide in a DRI conformation (D amino acids in a retro reversed sequence), henceforth named FOXO4 DRI, competes with FOXO4 for p53 binding in a dose dependent manner and doing so with higher affinity. Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Targeting cellular senescence with senotherapeutics: senolytics and senomorphics Zhang 2023 The FEBS Journal Wiley Online Library Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway Frontiers Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Pay in 4 interest-free payments of $7.15 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10




